Short- Term Outcome and One -Year Recurrence in Acute Pulmonary Embolism Patients With and Without Sleep - Disordered Breathing

Alexandria University0 个研究点目标入组 40 人开始时间: 2025年1月1日最近更新: 2026年1月21日

试验速览

阶段: 不适用
状态: 已完成
发起方: Alexandria University
入组人数: 40

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

This study aimsto compare short-termclinical outcomesand one-year recurrence rates in patients with acute pulmonary embolism with versus without sleep-disordered breathing, recruited from Alexandria MainUniversityHospital.

详细描述

This prospective observational study will include consecutive adult patients admitted to the Chest Diseases Department and related units at Alexandria Main University Hospital (AMUH) with a diagnosis of acute pulmonary embolism confirmed by CT pulmonary angiography and followed up with sllep study to asses the effect of sleep related breathing disorderon the recurrence of emboli.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age≥18years.
•Objectively confirmed acute pulmonary embolism by computed tomography pulmonary angiography (CTPA).
•Hemodynamically stable or clinically stabilized within 72 hours of admission. .Ability to provide informed consent.

排除标准

•.Known central sleep apnea without obstructive features. .Inabilityto undergo sleep study evaluation.
•Pregnancy

研究者

发起方

Alexandria University

申办方类型

Other

责任方

Sponsor

相似试验

招募中

3 期

Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexVentilator Associated Bacterial Pneumonia (VABP)Colistin Resistanrt ABCAcinetobacter Baumannii-calcoaceticus Complex

NCT07326540BioVersys SAS248

招募中

3 期

Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffuse large B-cell lymphoma (DLBCL)

2023-508259-38-00GWT-Tud GmbH302

招募中

3 期

Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC

2022-500395-57-00Merck Sharp & Dohme Corp.267

招募中

不适用

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

NCT07270861Fudan University3,000

招募中

不适用

Prognosis of Early-onset Anorexia NervosaAnorexia Nervosa

NCT07311356Assistance Publique - Hôpitaux de Paris140